Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Feasibility Trial Of Disappearing Tissue Tricuspid Valve

This article was originally published in The Gray Sheet

Executive Summary

CorMatrix Cardiovascular’s CorMatrix ECM tricuspid heart valve is a flexible, unstented valve that works as a replacement valve while also providing the scaffold on which the patient’s own tissue can form a new valve.

You may also be interested in...



New Products In Brief

CorMatrix Cardiovascular’s ECM

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations

With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel